Open Access

Efficacy and safety of aflibercept in metastatic colorectal cancer pretreated with bevacizumab: A report of five cases

  • Authors:
    • Julia Alcaide
    • Mayte Delgado
    • Marta Legerén
    • José Miguel Jurado
    • Isabel Blancas
    • Teresa Pereda
    • Jorge López
    • Margarita Garrido
    • María J. Sánchez
    • José L. García
    • Antonio Rueda
  • View Affiliations

  • Published online on: August 30, 2016     https://doi.org/10.3892/ol.2016.5068
  • Pages: 3127-3134
  • Copyright: © Alcaide et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Aflibercept is a recombinant fusion protein that acts by inhibiting tumoural angiogenesis. Efficacy data obtained in the VELOUR randomised study has contributed to the approval of aflibercept as a second‑line metastatic colorectal cancer (mCRC) treatment following an oxaliplatin‑based regimen. The present study reports a case series of five patients with mCRC, who were treated in two centres since 2011 in the Compassionate Use Program for aflibercept. All patients had a KRAS mutation and previously received palliative fluoropyrimidine‑oxaliplatin‑based chemotherapy with bevacizumab. A doublet with irinotecan combined with aflibercept was administered until progression of disease. The majority of patients received a greater number of aflibercept cycles than the median reported in the VELOUR study (12 vs. 7 cycles), with manageable and reversible toxicity. The most frequent adverse events observed were diarrhoea, neutropenia, fatigue, proteinuria and hypertension. Most cases obtained a progression‑free survival greater than the median reported in the VELOUR study (11 vs. 6.9 months) and, in a subgroup of patients previously treated with bevacizumab, and a median survival time of ~47 months was reached from the initial treatment of the disease. The present study contrasts the efficacy and safety results obtained from the pivotal VELOUR trial, and confirms that aflibercept, used in routine clinical practice outside of the clinical trial environment, is active and well‑tolerated following bevacizumab treatment.
View Figures
View References

Related Articles

Journal Cover

November-2016
Volume 12 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Alcaide J, Delgado M, Legerén M, Jurado JM, Blancas I, Pereda T, López J, Garrido M, Sánchez MJ, García JL, García JL, et al: Efficacy and safety of aflibercept in metastatic colorectal cancer pretreated with bevacizumab: A report of five cases. Oncol Lett 12: 3127-3134, 2016.
APA
Alcaide, J., Delgado, M., Legerén, M., Jurado, J.M., Blancas, I., Pereda, T. ... Rueda, A. (2016). Efficacy and safety of aflibercept in metastatic colorectal cancer pretreated with bevacizumab: A report of five cases. Oncology Letters, 12, 3127-3134. https://doi.org/10.3892/ol.2016.5068
MLA
Alcaide, J., Delgado, M., Legerén, M., Jurado, J. M., Blancas, I., Pereda, T., López, J., Garrido, M., Sánchez, M. J., García, J. L., Rueda, A."Efficacy and safety of aflibercept in metastatic colorectal cancer pretreated with bevacizumab: A report of five cases". Oncology Letters 12.5 (2016): 3127-3134.
Chicago
Alcaide, J., Delgado, M., Legerén, M., Jurado, J. M., Blancas, I., Pereda, T., López, J., Garrido, M., Sánchez, M. J., García, J. L., Rueda, A."Efficacy and safety of aflibercept in metastatic colorectal cancer pretreated with bevacizumab: A report of five cases". Oncology Letters 12, no. 5 (2016): 3127-3134. https://doi.org/10.3892/ol.2016.5068